Hims & Hers CFO sells 23,090 shares under 10b5-1 plan

Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe reported a sale of Class A common stock.

Rhea-AI Filing Summary

Hims & Hers Health, Inc. Chief Financial Officer Oluyemi Okupe reported a sale of Class A common stock. On 12/22/2025, the reporting person sold 23,090 shares at an average price of $35.7172, with trades executed in a price range of $35.36–$35.88. The filing states these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on May 21, 2025, which is designed to systematically execute trades over time.

After this transaction, the reporting person beneficially owns 94,333 shares of Class A common stock directly and 7,853 shares indirectly through the Oluyemi Okupe Separate Property Trust dated 9-1-2021.

Insider Trade Summary

Net Seller: 23,090 shares

Net Sell 2 txns

Insider Okupe Oluyemi

Role Chief Financial Officer

Sold 23,090 shs ($825K)

Type	Security	Shares	Price	Value
Sale	Class A Common Stock	23,090	$35.7172	$825K
holding	Class A Common Stock	--	--	--

Holdings After Transaction: Class A Common Stock — 94,333 shares (Direct); Class A Common Stock — 7,853 shares (Indirect, Held by Oluyemi Okupe Separate Property Trust dtd 9-1-2021)

Footnotes (2)

1. F1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025 by the Reporting Person.
2. F2. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $35.36-35.88. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did HIMS report in this Form 4?

Hims & Hers Health, Inc. reported that its Chief Financial Officer, Oluyemi Okupe, sold 23,090 shares of Class A common stock on 12/22/2025.

At what price did the HIMS CFO sell the shares?

The reported average weighted sale price was $35.7172 per share, with individual trades occurring between $35.36 and $35.88 per share.

Was the HIMS CFO’s share sale under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected under a Rule 10b5-1 trading plan adopted on May 21, 2025 by the reporting person.

How many HIMS shares does the CFO still own after this transaction?

After the reported sale, the CFO beneficially owns 94,333 shares of Class A common stock directly and 7,853 shares indirectly through the Oluyemi Okupe Separate Property Trust dated 9-1-2021.

What is the relationship of the reporting person to Hims & Hers Health (HIMS)?

The reporting person, Oluyemi Okupe, is identified as an officer of Hims & Hers Health, Inc., serving as its Chief Financial Officer.

Is this HIMS Form 4 filed for one person or multiple insiders?

The document indicates that the Form 4 is filed by one reporting person, not by a group.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/23/2025 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Okupe Oluyemi

(Last) (First) (Middle)

2269 CHESTNUT STREET, #523

(Street)

SAN FRANCISCO CA 94123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Hims & Hers Health, Inc. [ HIMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
12/22/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	12/22/2025		S(1)		23,090	D	$35.7172(2)	94,333	D
Class A Common Stock								7,853	I	Held by Oluyemi Okupe Separate Property Trust dtd 9-1-2021

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025 by the Reporting Person.

2. Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $35.36-35.88. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

Remarks:

	/s/ Kimberly Mather, Attorney-in-Fact for Oluyemi Okupe	12/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.